TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin for Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-ulcer dyspeptic patients who fulfill post-prandial distress syndrome according to the Rome III Criteria~* Active dyspeptic symptom~* Normal upper endoscopy~* Urea Breath Test -ve or Rapid urease test -ve~* Not typical gastroesophageal reflux or biliary colic symptoms, but presence of infrequent acid reflux is allowed~Exclusion Criteria:~* No active dyspeptic symptom~* Allergic to rifaximin~* Recent antibiotics use in the past 8 wk~* Recent PPI or H2RA in past 4 wk~* On anti-coagulants, anti-convulsant or oral contraceptives~* On NSAIDs, aspirin or Clopidogrel~* Pregnancy or breast feeding~* Previous gastric surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: I-gel Versus Classic-Laryngeal Mask Airway (C-LMA) as a Conduit for Tracheal Intubation Using Ventilating Bougie

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 60 years~* Gender : either sex~* American society of Anaesthesiologist's Physical Status (ASAPS) I and II~* Patients posted for surgery requiring general anaesthesia and endotracheal intubation.~Exclusion Criteria:~* age \<18 years and \> 60 years~* ASAPS III or IV~* Obesity body mass index \>25~* Patients with mouth opening \<2cms~* Patients with Malampatti grade III and IV~* Patients having history of gastro-esophageal reflux disease~* Patients with history of inadequate fasting~* Patients with known or anticipated difficult tracheal intubation or face-mask ventilation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group-I (Type: ACTIVE_COMPARATOR): Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
- Group-C (Type: ACTIVE_COMPARATOR): Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. patient Aged between 18 and 45 years.~2. singleton viable pregnancy.~3. non scared uterus.~Exclusion Criteria:~1. systemic illness (DM,Hypertension, renal disease, liver disease, sickle cell disease)~2. known congenital fetal anomalies.~3. multiple pregnancy.~4. intra uterine fetal death.~5. anatomical defect of pregnant uterus~6. abnormally located placenta or placental anomalies~7. morbid obesity~8. missing records~9. unwilling to incorporate in the study.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Stage V chronic kidney disease preparing to start hemodialysis~* Exchange of an existing catheter to a cuffed, tunneled catheter OR planned vascular access with a cuffed, tunneled catheter~* CVC used for hemodialysis made of alcohol-resistant polymers ie. carbothane~Exclusion Criteria:~* Patients receiving catheters not made of alcohol resistant polymers~* Critically ill patients in ICU setting~* Patients with acute renal failure, who will likely not require prolonged vascular access ( ie. \> months)~* Patients with maturing fistulas/graft creation within 2 months~* Patients with planned antibiotic treatment courses lasting longer than 4 weeks from the date of new catheter insertion~* Patients receiving a new cuffed, tunneled catheter over a guide wire, if a fibrin sheath angioplasty was not performed after removing the previous dysfunctional catheter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 % ethanol/ 4 % sodium citrate group (Type: EXPERIMENTAL): For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
- Heparin 1000 U/ml (Type: EXPERIMENTAL): For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive H. Pylori status;~* Presence of upper gastro-intestinal symptoms;~* Mental and legal ability to sign informed consent.~Exclusion Criteria:~* Previous surgery of the GI tract;~* Clinically significant impairment of renal or hepatic function;~* Severe unstable cardiovascular, pulmonary or endocrine disease;~* Barrett's oesophagus or high-grade dysplasia;~* Dysphagia or vomiting as major symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OAC 7 days (Type: ACTIVE_COMPARATOR): Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
- OBMT 10 days (Type: EXPERIMENTAL): OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of KRN23 in X-linked Hypophosphatemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older~2. Clinical diagnosis of XLH~3. TmP/GFR is less than 2.0 mg/dL~4. GFR is 60 mL/min or above~Exclusion Criteria:~1. Have any sign of active infectious disease or have had an infection requiring treatment with antibiotics within three weeks prior to screening~2. History of known immunodeficiency~3. Lactating females, female patients who are pregnant or planning to become pregnant during the study~4. Use of a pharmacologic vitamin D metabolite or its analog, phosphate, calcimimetics, and ingestion of aluminum hydroxide antacids within 10 days prior to screening and dosing~5. Use of any supplement contained phosphate, calcium and/or vitamin D within 10 days prior to screening and dosing~6. Receipt of live (attenuated) vaccine within 3-months prior to screening~7. Have any condition which, in the opinion of the Investigator, could present a concern for either patient safety or difficulty with data interpretation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KRN23 (Type: EXPERIMENTAL): Single IV or SC administration on day 1
- Placebo (Type: PLACEBO_COMPARATOR): Single IV or SC administration on day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present \>/= 1 month by history or exam~* BCVA is worse than 20/200 at time of screening~Exclusion Criteria:~* Corneal or lenticular abnormalities that preclude fundus observation~* Ongoing ocular infection, inflammation or history of herpetic corneal lesion~* Current or prior retinal detachment or retinal tears or breaks or intraocular tumor~* More than 1 severe vitreous hemorrhage within 6 months~* Previous vitrectomy for any reason~* Hemorrhage is exclusively pre-retinal, or old \& organized~* Prior Vitrase for intravitreal injection in either eye~* No light perception in either eye at any time~* Known contraindications to study medication~* Sickle cell disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitrase (Type: EXPERIMENTAL): Single Hyaluronidase ophthalmic intravitreal injection
- Placebo (Type: PLACEBO_COMPARATOR): Single Saline solution intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triclosan Toothpaste in the Maintenance Phase of Peri-implantitis Treatment.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged between 18-70 years;~* general good health;~* minimum of 1 dental implant in function for at least one year with untreated peri-implantitis defined as: probing depth (PD) ≥ 5 mm, bleeding on probing (BOP) or suppuration, radiographic bone loss involving 2 mm from the upper border of the intrabony portion of the implant.~Exclusion Criteria:~* untreated periodontitis (defined as ≥ 6 sites with PD ≥ 5 mm);~* periodontal treatment within three months prior to entering the study;~* inability to perform proper supragingival plaque control (e.g. due to improper prosthesis design or lack of skills);~* diabetes;~* pregnancy;~* nursing;~* history of allergies to triclosan, fluoride or any other ingredient of oral care products;~* alcohol or drug abuse;~* any systemic diseases that could affect post-operative healing;~* any systemic diseases that required antibiotic premedication for routine dental therapy;~* long-term use of mouthrinses, anti-inflammatory medications or any other drug that could interfere with the study outcomes within three months prior to entering the study;~* antibiotics use within six months prior to entering the study;~* participation in any other clinical study within three months prior to entering the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Test: Triclosan toothpaste (Type: EXPERIMENTAL): To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction.
- Control: Fluoride toothpaste (Type: PLACEBO_COMPARATOR): To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing Carbonated Drink With Water as a Solvent for Colonoscopy Solution

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Age \> 18 years~  * Non-emergency / non urgent colorectal diseases (IBD, suspected colonic polyps, colorectal cancer)~ * Screening Colonoscopy~Exclusion Criteria:~* Age \<18 years Pregnancy Intestinal obstruction Unfit patient Acute or serious illness Coagulopathy Unwilling patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Water (Type: ACTIVE_COMPARATOR): Water will be used as solvent for sodium phosphate
- Zero calorie carbonated drink (Type: ACTIVE_COMPARATOR): Zero calorie carbonated drink will be used as solvent for sodium phosphate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* Receiving Kaletra, stavudine, and lamivudine for greater than 6 years (through Abbott M97-720 study)~* Planning to switch from stavudine to tenofovir~Exclusion Criteria:~* Will continue to receive stavudine

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men or women between the ages of 18 and 45 years old~Exclusion Criteria:~* History (including family history) or symptoms of, or risk factors for bleeding~* History (including family history) of or risk factors for a hypercoagulable or thrombotic condition~* Absolute/relative contraindication to anticoagulation or treatment with specific anticoagulants~* History of major surgery, severe trauma or bone fracture within 3 months prior to dosing; or planned surgery within 1 month after dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Module 3 (210 mg bolus) original (Type: EXPERIMENTAL): 210 mg PRT064445 given as a single IV bolus
- Module 3 (420 mg bolus) original (Type: EXPERIMENTAL): 420 mg PRT064445 given as a single IV bolus
- Module 3 (210 mg) lyophilized (Type: EXPERIMENTAL): 210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
- Module 3 Placebo (Type: PLACEBO_COMPARATOR): Placebo administered intravenously (IV) as a bolus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Receiving care Post-lung transplant at University of Wisconsin Hospital~* Healthy adult~Exclusion Criteria:~* Allergy to eggs~* Moderate to severe febrile illness~* Active treatment for acute rejection~* Received season's influenza vaccine prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vaccine, Post-transplant (Type: None): Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
- Vaccine, Healthy Control (Type: None): Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. History of chronic non-malignant pain (originating from a non-malignant source) with condition(s) underlying the chronic pain of greater than or equal to (≥) 2 months' duration before the screening visit.~2. Taking oral, transdermal, intravenous (IV), or subcutaneous (SC) opioids for chronic non-malignant pain for ≥1 month.~3. No known history of chronic constipation prior to the initiation of opioid therapy.~4. Currently taking laxative therapy for ≥30 days and willing to discontinue all laxative therapy at the start of screening period and use only study-permitted rescue laxatives throughout the screening and double-blind treatment periods..~Key Exclusion Criteria:~1. Prior treatment with oral MNTX.~2. Prior treatment with SC MNTX within 30 days of screening.~3. Women who are pregnant, breastfeeding, or plan to become pregnant during the study.~4. Fecal incontinence, rectal prolapse, fecal ostomy or other clinically significant gastrointestinal disorders such as inflammatory bowel disease or clinically significant irritable bowel syndrome that would have made bowel movement assessment inaccurate.~5. Current treatment with partial opioid agonists (for example; buprenorphine) or combination agonists/antagonists.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MNTX 150 mg (Type: EXPERIMENTAL): Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).
- MNTX 300 mg (Type: EXPERIMENTAL): Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
- MNTX 450 mg (Type: EXPERIMENTAL): Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spinal or Epidural Fentanyl or Sufentanil for Labour Pain in Early Phase of the Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Primiparous parturients~* In early phase of labour (cervical dilatation at or under 5 cm)~* No prior opioids by any route of administration within past 120 min~* Pain at or over 80 mm on 0-100 mm visual analog scale during contraction~Exclusion Criteria:~* Allergy for any of the medications used~* Contraindications for epidural/spinal analgesia~* BMI at the time of delivery under 20 or over 35 kg/m2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Spinal fentanyl (Type: ACTIVE_COMPARATOR): 20 micrograms of intrathecally administered fentanyl in single dose. Total volume of intrathecal injection 2 ml.
- Epidural fentanyl (Type: EXPERIMENTAL): 100 micrograms of epidurally administered fentanyl in a single dose. Total volume of epidural injection 7 ml.
- Spinal sufentanil (Type: ACTIVE_COMPARATOR): 5 micrograms of intrathecally administered sufentanil in a single dose. Total volume of intrathecal injection 2 ml.
- Epidural sufentanil (Type: EXPERIMENTAL): 20 micrograms of epidurally administered sufentanil in a single dose. Total volume of epidural injection 7 ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete